IperionX (ASX:IPX) analysts see $9 target, but 2026 is about execution not earnings

GenX scale-up, Titan economics, customer volumes must land

Can IperionX (ASX:IPX) really reach the holy grail of titanium manufacturing and emerge as a formidable titanium producer on both the ASX and Nasdaq?

Many investors are following the IperionX story, which has ridden a strong wave of momentum after the US push to reshore manufacturing. Titanium remains one of the more underappreciated metals and mineral opportunities in the market. It offers a superior strength-to-weight ratio compared with steel and is increasingly being used across aerospace, defence, robotics, and other advanced industrial applications.

At present, two analysts cover IperionX, with an average buy price target of $9, reflecting market confidence that the company can scale production and build a deeper customer pipeline. The key question, however, is whether IperionX can actually deliver on that promise at scale.

What are the Best ASX Stocks to invest in right now?

Check our buy/sell tips

From Lab to Commercial, The Ramp Is Real

Let’s start with what is currently working for the company.

Current powder production capacity stands at 200 metric tonnes per year at its Virginia titanium manufacturing campus, representing a 60x increase from the pilot scale achieved roughly 12 months ago.

The company has also invested in new equipment for CY2026, including cold isostatic presses, sintering furnaces, and hydride-dehydride furnaces, all aimed at expanding its advanced manufacturing capability well beyond current powder capacity as it moves toward its 1,400 tpa target by mid-2027.

If we look at the customer pipeline, it is still relatively small, but purchase orders are beginning to materialise. These include a US$100,000 Carver Pump prototype order for Navy applications and a US$300,000 American Rheinmetall order for 700 titanium components for U.S. Army heavy ground combat systems.

That tells us the company is securing smaller-scale orders that match its current manufacturing capacity, allowing it to test, qualify, and prove its parts, which is normal at this stage of the scale-up. The current manufacturing line is doing what it is supposed to at this early validation stage.

GenX is the long-term manufacturing catalyst

GenX is IperionX’s upgraded version of its titanium production system. The company is continuing to iterate on its manufacturing line, with the aim of lowering titanium production costs per kilogram and reducing operating cost requirements. Over the long term, that is clearly important for improving margins.

Under the current HAMR system, doubling capacity would likely require IperionX to effectively expand into another plant using the same process. With GenX, however, the scaling pathway appears more flexible, as capacity can be added in smaller, lower-cost increments rather than through large, expensive step changes.

That matters because it suggests IperionX could potentially grow toward its 10,000-tonne target without needing to raise as much capital from shareholders along the way. That said, this remains a longer-term plan and theory for now, and the company still needs to execute on it. Delivery against that pathway will be a key catalyst in the broader manufacturing scale-up story. But the company is clearly thinking about the best and cheapest pathway to its manufacturing capacity plans.

IperionX’s Red Flag, Corporate Costs Jump 5x as Losses Double

What we are starting to see, however, based on the latest financials, is growing operating cost inflation, with losses roughly doubling and corporate costs spiking. While there was also a one-off legal dispute, the most striking line item was corporate and administrative expenses, which jumped from US$3.3 million to US$16.2 million, nearly a fivefold increase. Management attributed this to a mix of higher salaries and broader overhead growth as operations begin to develop and scale.

This is a key watchpoint for investors because the recent capital raise should ideally be directed primarily toward manufacturing scale-up, not absorbed disproportionately by salaries and corporate overhead. If too much of that funding is consumed by back-office cost growth rather than production expansion, it could weaken confidence in how efficiently the company is executing its scale-up strategy.

The investor’s takeaway for IPX

IperionX does have a real path to becoming a formidable titanium player, but CY2026 is not a revenue inflection year. It is a credibility inflection year.

What the company needs to prove over this period is threefold: first, that GenX works at commercial scale; second, that the Titan Project is economically developable; and third, that early prototype customer engagements can convert into meaningful volume commitments. If all three are achieved, the investment thesis strengthens materially ahead of the planned 1,400 tpa commissioning in mid-2027, which is the true revenue inflection point.

Investors should not expect meaningful improvement in the P&L during CY2026. Cash burn is likely to remain elevated as expansion capex peaks. The key signal to watch is not near-term financial performance, but whether the company can deliver the technical and commercial milestones needed to validate the scale-up story.

Based on its current market capitalisation, a meaningful portion of the stock’s price already appears to reflect future growth. That does not mean the share price cannot keep rising, but it does suggest the stock is not cheap relative to the company’s early-stage nature. At this point, we would rather wait for more confirmation around manufacturing scale-up and GenX validation before becoming more constructive.